PEPTIDE RESEARCH TOPIC

Ipamorelin Research Peptide

Explore Ipamorelin research context, terminology, comparisons, analytical information, and common questions.

TOPIC OVERVIEW

About Ipamorelin

Identity and names

Ipamorelin is the formal name of a synthetic pentapeptide growth hormone secretagogue.

  • Ipa is informal shorthand; Ipamorelin is distinct from GHRH analogues such as CJC-1295, Sermorelin, and Tesamorelin.

Compound type

The molecule is a selective growth hormone secretagogue containing non-natural amino-acid residues.

  • Its design and receptor target place it in a different compound class from GHRH analogues even though both can affect growth-hormone signaling.

Mechanism

Ipamorelin activates the growth hormone secretagogue, or ghrelin, receptor rather than the GHRH receptor.

  • Research examines episodic growth-hormone release, receptor selectivity, endocrine markers, exposure time, and differences from older GHRPs or GHRH analogues.

Research focus and evidence

Preclinical pharmacology reported GH release with less ACTH and cortisol stimulation than several older secretagogues in the tested models.

  • A small human volunteer study characterized short-lived exposure and a pharmacodynamic GH response, but broader controlled human evidence remains limited.

Regulatory status and limits

Ipamorelin is not generally approved as a therapeutic medicine and is prohibited in sport under current World Anti-Doping Agency rules.

  • Available studies do not establish broad effectiveness, long-term safety, or combination protocols, and research products require independent identity and quality verification.
Topics covered
  • ghrelin receptor terminology
  • growth hormone secretagogues
  • comparison with GHRH analogs
  • storage and stability
  • identity and analytical records
Common names and related terms: ipamorelin, ipa, ipamorelin peptide
EVIDENCE PROFILE

Ipamorelin Research Evidence

A concise view of registered clinical research, PubMed-indexed literature, evidence stage, and important limitations.

LAST VERIFIEDSeptember 30, 2026
Registered records3
Active studies1
Completed studies2
PubMed records54
Compound typeGrowth hormone secretagogue
AliasesNNC 26-0161
Evidence stageLimited early clinical evidence
U.S. regulatory contextNot FDA-approved
CLINICAL REGISTRY

Selected registered research

NCT00672074Phase 2 · Completed

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

NCT01280344Phase 2 · Completed

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT07717866Not specified · Active, not recruiting

Trifecta Research Study

INDEXED LITERATURE

Selected PubMed records

PMID 98498221998 Nov · European journal of endocrinology

Ipamorelin, the first selective growth hormone secretagogue.

PMID 414764242026 Jan · The American journal of sports medicine

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

PMID 419666392026 Aug · Sports medicine (Auckland, N.Z.)

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

How to interpret this profile

Registry and publication counts describe discoverable records, not proof of effectiveness or safety. Study design, compound identity, population, endpoints, and regulatory context must be reviewed individually.

Primary sources: ClinicalTrials.gov · PubMedCounts are dated exact-term search snapshots, not evidence-quality scores. Related compounds, spelling variants, and non-indexed literature may not be included.

Displayed records are selected for relevance and recency; the page does not reproduce the complete source databases.

START HERE

Essential Ipamorelin guides

IPAMORELIN KNOWLEDGE ARTICLESPage 1 of 16
03
KNOWLEDGE ARTICLE

CJC 1295 Ipamorelin Flushing: Causes & Duration

CJC 1295 ipamorelin flushing is a common, short-lived reaction to this peptide stack. Learn why it happens, how long it lasts, and how to reduce it.

↗
04
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin: DAC or No DAC?

CJC-1295 ipamorelin DAC or no DAC? Compare half-life, dosing frequency, and GH release patterns to see which version fits a research protocol.

↗
13
KNOWLEDGE ARTICLE

CJC vs Ipamorelin: Key Differences Explained

CJC vs ipamorelin: how these two growth hormone peptides differ in half-life, dosing, and research use, plus safety notes and what to ask a clinician.

↗
14
KNOWLEDGE ARTICLE

CJC-1295 Without DAC & Ipamorelin Dosage Guide

Typical cjc 1295 without dac ipamorelin dosage ranges, injection timing, blend ratios, and weekly totals for research use, plus important safety notes.

↗
15
KNOWLEDGE ARTICLE

Does Ipamorelin Burn Fat? What Research Shows

Does ipamorelin burn fat? Here's what research shows about ipamorelin, growth hormone release, appetite, and realistic fat loss expectations in humans.

↗
17
KNOWLEDGE ARTICLE

CJC-1295 DAC vs Ipamorelin: Key Differences

CJC-1295 DAC vs ipamorelin explained: how these two growth hormone peptides differ in half-life, receptor targets, dosing frequency, and stacking.

↗
18
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin for Men: Benefits and Risks

CJC-1295 ipamorelin for men is a research peptide stack studied for growth hormone release. Learn how it works, protocols, side effects, and safety.

↗